Johnson & Johnson Starts 2026 on Firm Footing as Drug Growth Offsets a More Measured MedTech Pace
A raised full-year sales outlook, stronger adjusted earnings and continued momentum in oncology and immunology kept Johnson & Johnsonβs growth story intact, even as revenue eased modestly from the prior quarter.
π Key Takeaways
Johnson & Johnson opened 2026 with a solid, if not flawless, quarter. First-quarter sales were $24.1B, up 6.4% operationally, while adjusted net earnings reached $6.6B and adjusted EPS came in at $2.70. Management also lifted its 2026 operational sales guidance to $100.2B at the midpoint and raised adjusted operational EPS guidance by $0.02 to a range of $11.30-$11.50.
Against the prior report, the picture is modestly improved rather than cleanly stronger. Revenue was down from $24.6B in the fourth quarter of 2025, and both Innovative Medicine and MedTech posted lower sequential sales. But adjusted EPS improved from $2.46 in the prior quarter, while managementβs guidance moved higher, suggesting the core launch portfolio is doing enough to offset normal seasonality and lingering legacy drags.
π What Drove the Quarter
The main engine remained Innovative Medicine. Segment sales were $15.4B, up 7.4% operationally despite a roughly 920 bps headwind from Stelara. Darzalex led again with $4.0B in sales and about 18% operational growth, while Carvykti reached roughly $600M and Rybrevant plus Lazcluze delivered $257M, up 80.5%. Tremfya also stayed on a very strong trajectory, with sales up 63.8%.
Just as important, management used the quarter to reinforce the next wave of growth. The company highlighted FDA approval for its new oral psoriasis therapy, continued momentum in Caplyta, and an expanding bladder cancer opportunity after broader reimbursement support for its recently launched therapy. That keeps the medium-term story centered on new products rather than only on mature blockbusters.
π₯ MedTech Trends Were Solid, But Slower
MedTech was still positive, though less forceful than the pharmaceutical side. First-quarter MedTech sales were $8.6B, up 4.6% operationally. Electrophysiology grew 9.5%, Abiomed rose 14.4%, and Shockwave increased 18.1%, all pointing to continued strength in cardiovascular platforms. Surgical Vision grew 6.0%, while surgery overall rose just 1.2% as transformation work, pricing pressure and China volume-based procurement weighed on the comparison.
Compared with the fourth quarter of 2025, MedTech growth cooled from 5.8% and sales slipped from $8.8B. That does not break the thesis, but it does suggest J&J still needs its newer cardiovascular and robotics platforms to do more of the lifting as the year progresses.
βοΈ Margins, Cash Flow and Capital Allocation
The cleaner headline on earnings came with some pressure underneath. Adjusted income before tax as a percentage of sales was 32.5% in the quarter, with Innovative Medicine margin at 39.7% and MedTech margin at 22.3%. Management attributed the pressure largely to heavier early-year launch investment, tariffs and product mix, while reiterating that full-year pre-tax operating margin should still improve by at least 50 bps.
Cash flow was softer in the quarter, with free cash flow at about $1.5B, but management said timing effects and higher capital spending were expected and kept its full-year free cash flow outlook at roughly $21B. J&J also raised its dividend by 3.1%, reinforcing the balance-sheet story even as net debt moved to about $33B.
π What Matters Next
The latest report keeps Johnson & Johnsonβs broader message intact: growth is becoming more dependent on launches, pipeline execution and portfolio mix, and less dependent on legacy franchises. The quarter was not stronger across every line item than the last one, but it was good enough to support higher full-year sales guidance and preserve managementβs line of sight to faster growth deeper into the decade.
For investors, the key watchpoints now are straightforward: whether the psoriasis, bladder cancer and neuroscience launches continue to scale; whether MedTech re-accelerates in the back half; and whether J&J can convert a strong product cycle into sustained margin expansion. On that score, the first quarter looked more like steady progress than a blowout, but it still moved the story forward.
